R Squared’s Enanta Pharmaceuticals ENTA Stock Holding History

R Squared’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,300	Closed	-$13.2K	–	656
2024 Q4	$13.2K	Buy	+2,300	New	+$22.1K	0.01%	1057

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R Squared's ENTA Position: Q1 2025 in Review

R Squared sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 2,300 shares — an estimated $13.2K sold.

R Squared first reported a position in ENTA in Q4 2024 and held it in 1 quarter. The position peaked at $13.2K in Q4 2024. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

R Squared reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,300 Enanta Pharmaceuticals shares in Q1 2025, an estimated $13.2K.
R Squared first reported a position in Enanta Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Enanta Pharmaceuticals position peaked at $13.2K in Q4 2024.
109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.